Payment overview · 2025
General Payments
$109.98
5 reported records · 3 companies
Healthcare provider profile · identity verified
Ann D. Layton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, AR · NPI 1700879970
Verified facts
What the public records show
CMS Open Payments records show Ann D. Layton, MD received $109.98 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.31 | 33.9% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $36.82 | 33.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.85 | 32.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.98 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $36.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
118 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 120 |
| Omeprazole | Omeprazole | 382 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 92 |
| Tramadol Hcl | Tramadol Hcl | 275 | 59 |
| Gabapentin | Gabapentin | 264 | 74 |
| Furosemide | Furosemide | 237 | 65 |
| Alprazolam | Alprazolam | 206 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 44 |
| Potassium Chloride | Potassium Chloride | 173 | 48 |
| Losartan Potassium | Losartan Potassium | 172 | 43 |
| Methylprednisolone | Methylprednisolone | 172 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 44 |
| Clonazepam | Clonazepam | 151 | 23 |
| Montelukast Sodium | Montelukast Sodium | 149 | 42 |
| Lisinopril | Lisinopril | 146 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 56 |
| Trazodone Hcl | Trazodone Hcl | 143 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 132 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 29 |
| Azithromycin | Azithromycin | 128 | 84 |
| Simvastatin | Simvastatin | 127 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 31 |
| Farxiga | Dapagliflozin Propanediol | 118 | 23 |
| Meloxicam | Meloxicam | 117 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 42 |
| Ozempic | Semaglutide | 110 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | 26 |
| Sertraline Hcl | Sertraline Hcl | 102 | 23 |
| Metformin Hcl | Metformin Hcl | 100 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 27 |
| Famotidine | Famotidine | 92 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 57 |
| Fluconazole | Fluconazole | 84 | 48 |
| Bupropion Xl | Bupropion Hcl | 80 | 25 |
| Jardiance | Empagliflozin | 80 | 18 |
| Glipizide | Glipizide | 74 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 21 |
| Terazosin Hcl | Terazosin Hcl | 74 | 17 |
| Carvedilol | Carvedilol | 70 | 19 |
| Atenolol | Atenolol | 69 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 20 |
| Mirtazapine | Mirtazapine | 65 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 17 |
| Levofloxacin | Levofloxacin | 64 | 45 |
| Eliquis | Apixaban | 63 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 16 |
| Spironolactone | Spironolactone | 61 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 40 |
| Prednisone | Prednisone | 57 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 20 |
| Gemfibrozil | Gemfibrozil | 55 | 14 |
| Sucralfate | Sucralfate | 54 | 22 |
| Buspirone Hcl | Buspirone Hcl | 53 | 17 |
| Nifedipine Er | Nifedipine | 52 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | 15 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 20 |
| Glipizide Er | Glipizide | 44 | suppressed |
| Estradiol | Estradiol | 41 | suppressed |
| Linzess | Linaclotide | 41 | 14 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Celecoxib | Celecoxib | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 31 |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 16 |
| Dexamethasone | Dexamethasone | 32 | 22 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Ssd | Silver Sulfadiazine | 28 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 12 |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 19 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 13 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.98 · 5 records | Novo Nordisk Inc | FARXIGA, Omnipod, Ozempic, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error